Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2113-2117

  Gercel Taylor, Cicek ^a   Scobee, Jeremy J ^a   Taylor, Douglas D ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Chemotherapy; Cisplatin; Ovarian cancer; Taxol; Topotecan

Indexed keywords

CISPLATIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; TIOGUANINE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CLONE; CELL COUNT; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; OVARY CANCER; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; FEMALE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MUTATION; OVARIAN NEOPLASMS; PACLITAXEL; THIOGUANINE; TOPOTECAN; TRETINOIN;

EID: 21344451856     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Berek JS and Hacker NF: Practical Gynecologic Oncology. 2nd edition. Baltimore, MD, Williams & Wilkins, pp. 327, 1994.
2. Baak JPA, Wisse-Brekemans ECM, Langley FA, Talerman A and Delemarre JFM: Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 39: 1340-1346, 1986.
3. Holschneider CH, Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10, 2000.
4. Van Nagell JR Jr, Gallion HH, Pavlik EJ and DePriest PD: Ovarian cancer screening. Cancer 76(10 Suppl): 2086-2091, 1995.
5. Manahan KJ, Scobee JJ, Spanos WC, Taylor DD and Gercel-Taylor C: Effect of retinoic acid on the genomic stability of ovarian cancer cells. In press, 2004.
6. De las Alas MM, Aebi S, Fink D, Howell SB and Los G: Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Nat Cancer Inst 89(20): 1537-1541, 1997.
7. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R and Howell SB: Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087-3090, 1996.
8. Heppner GH and Miller FR: The cellular basis of tumor progression. Int Rev Cytol 177: 1-56, 1998.
9. Fialkow PJ: Clonal origin of human tumors. Annu Rev Med 30: 135-143, 1979.
10. Tanooka H: Monoclonal growth of cancer cells: experimental evidence. Jpn J Cancer Res 79: 657-665, 1988.
11. Nowell PC: The clonal evolution of tumor cell populations. Science 194: 23-28, 1976.
12. Eshelman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Wilson JKV, Veigl ML, Sedwick WD and Markowitz SD: Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10: 33-37, 1995.
13. Formelli F and Cleris L: Synthetic retinoid fenretinidine is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53: 5374-5376, 1993.
14. Loeb LA: A mutator phenotype in cancer. Cancer Res 61: 3230-3239, 2001.
15. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D et al: Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88(11): 4296-4303, 1996.